Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Chemo in Metastatic Pancreatic Adenocarcinoma
NCT02436668Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- May 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of ibrutinib in pancreatic adenocarcinoma (PDAC), sponsored by Pharmacyclics. Started May 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02436668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436668.